Gemifloxacin Online

Buy Factive (Gemifloxacin) quinolone antibacterial medication
Cheap qualitative Gemifloxacin Mesylate 320 mg tablets online



Gemifloxacin has in vitro activity against a wide range of Gram-negative and Gram-positive microorganisms. Factive (Gemifloxacin Mesylate) pills are bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the minimum inhibitory concentrations (MICs). This drug acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV (TOPO IV), which are essential for bacterial growth. Streptococcus pneumoniae showing mutations in both DNA gyrase and TOPO IV (double mutants) are resistant to most fluoroquinolones. Gemifloxacin has the ability to inhibit both enzyme systems at therapeutically relevant drug levels in S. pneumoniae (dual targeting), and has MIC values that are still in the susceptible range for some of these double mutants. However, the presence of double mutants was not evaluated in clinical trials; therefore, the clinical significance of these in vitro data are unknown.

The mechanism of action of quinolones, including gemifloxacin, is different from that of macrolides, beta-lactams, aminoglycosides, or tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to gemifloxacin and other quinolones. There is no known cross-resistance between gemifloxacin and the above mentioned classes of antimicrobials.

The main mechanism of fluoroquinolone resistance is due to mutations in DNA gyrase and/or TOPO IV. Resistance to gemifloxacin develops slowly via multistep mutations and efflux in a manner similar to other fluoroquinolones. The frequency of spontaneous mutation is low (10-7 to < 10-10). Although cross-resistance has been observed between gemifloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to gemifloxacin.

Gemifloxacin (Factive) pills have been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the Indications and Usage section.

Aerobic Gram-positive microorganisms

  • Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])

    MDRSP: multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC >= 2 mcg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

    Aerobic Gram-negative microorganisms

  • Haemophilus influenzae
  • Haemophilus parainfluenzae
  • Klebsiella pneumoniae (many strains are only moderately susceptible)
  • Moraxella catarrhalis

    Other microorganisms

  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

    The following data are available, but their clinical significance is unknown.

    Gemifloxacin Mesylate (Factive) pills exhibit in vitro minimal inhibitory concentrations (MICs) of 0.25 mcg/mL or less against most (.90%) strains of the following microorganisms; however, the safety and effectiveness of gemifloxacin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials:

    Aerobic Gram-positive microorganisms

  • Staphylococcus aureus (methicillin-susceptible strains only)
  • Streptococcus pyogenes

    Aerobic Gram-negative microorganisms

  • Acinetobacter lwoffii
  • Klebsiella oxytoca
  • Legionella pneumophila
  • Proteus vulgaris

    Recent posts:

  • Order Factive (Gemifloxacin Mesylate) Online
  • Factive prescribing information